Csl vifor and travere therapeutics announce ema has accepted for review the conditional marketing authorization application for sparsentan for the treatment of iga nephropathy

St. gallen, switzerland & san diego--(business wire)--csl vifor and travere therapeutics, inc. (nasdaq: tvtx) today announced that the ema has accepted for review the conditional marketing authorization (cma) application for sparsentan for the treatment of igan, a rare kidney disorder and a leading cause of end-stage kidney disease (eskd). the ema will review the application under the centralized marketing authorization procedure and a review decision on a potential approval is expected in the
TVTX Ratings Summary
TVTX Quant Ranking